In lung cancer, an association was made between drastic clinical response to epidermal
growth factor receptor (EGFR) inhibitors and the presence of somatic mutations within the …

Context.—Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are molecular-
targeted drugs that are innovatively effective for non–small cell lung carcinomas with EGFR …

Recently it has been reported that mutations in the tyrosine kinase domain of the epidermal
growth factor receptor (EGFR) gene occur in a subset of patients with lung cancer showing a …

INTRODUCTION: Mutations in the tyrosine kinase domain of the epidermal growth factor
receptor (EGFR) are frequently detected in lung adenocarcinomas with bronchioloalveolar …

The discovery that mutation of the tyrosine kinase domain of the epidermal growth factor
receptor (EGFR) gene occurs in a subset of lung cancers and predicts for sensitivity to …

Epidermal growth factor receptor (EGFR) mutations are a potential predictor of the
effectiveness of EGFR inhibitors for the treatment of lung cancer. Although EGFR mutations …

Background: Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor
receptor (EGFR) gene in lung cancers are associated with increased sensitivity of these …

Introduction: Epidermal growth factor receptor (EGFR) signaling pathway plays a crucial role
in the development and progression of lung cancer. We searched for mutations of EGFR …

Somatic mutations in the epidermal growth factor receptor gene (EGFR) are detected in a
subset of lung adenocarcinomas, particularly bronchioloalveolar carcinoma (BAC) and …

Context.—A subset of lung adenocarcinomas appears preferentially sensitive to epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). EGFR-activating mutations …